Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AP Pharma, a specialty pharmaceutical company that develops products using Biochronomer polymer-based drug delivery technology, has appointed Stephen Davis to its board of directors.
Subscribe to our email newsletter
Mr Davis was the chief executive officer for Neurogen Corporation, which was recently acquired by Ligand Pharmaceuticals. His appointment brings the number of AP Pharma board members to seven.
Mr Davis joined Neurogen in 1994, where he most recently served as the organisation’s chief executive officer and president. Prior to joining Neurogen, he was employed by Milbank, Tweed, Hadley & McCloy as a corporate and securities attorney. Previously, Mr Davis practiced as a Certified Public Accountant with Arthur Andersen & Co.
Paul Goddard, chairman at AP Pharma, said: “Steve’s industry experience and extensive business acumen will make him a valuable addition to AP Pharma’s board of directors as we continue to advance APF530 towards commercialisation for the prevention of chemotherapy-induced nausea and vomiting.”
Mr Davis, said: “As AP Pharma approaches its PDUFA date for APF530, I am excited to have the opportunity to join the Company’s board of directors. It is a transformational time in AP Pharma’s history, and I look forward to working with the board and management team.”